Switching From Hormone Pellets to Patches: What Actually Happens

The HRT Index Editorial TeamIndependent women's health research

Last reviewed:August 31, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 31, 2026 · Last verified: August 31, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Before you schedule another pellet insertion

Get your implant record, separate the estrogen and testosterone decisions, and confirm a written handoff before you pay for a patch program.

Match my situation to the right care path

We may earn a commission from some provider links on this page. The cheapest route below may earn us nothing. Our affiliate disclosure.

Switching from hormone pellets to patches is possible, but there is no validated 1:1 conversion and no universal waiting period. The plan starts with your insertion date, the milligrams of every implanted hormone, whether testosterone was included, and whether you have a uterus. A prescriber then chooses and times an FDA-approved estradiol patch by clinical response.

That is the real answer. You can leave the pellet cycle. You just cannot do it safely with a conversion chart and a calendar guess.

Best for you if:

You have a hormone pellet in now and do not want another insertion
You want systemic estrogen in an FDA-approved form that can be adjusted or stopped
You can get the implant record before the new prescription is finalized
You want to compare an insured visit, a cash-pay shipped program, and a local prescription route

Not for you if:

You are deciding whether to start pellets — read our testosterone pellets versus cream comparison instead
You have unexplained vaginal bleeding. That gets evaluated before a hormone change, full stop
You have chest pain, trouble breathing, sudden one-sided weakness, sudden severe leg swelling, or a hot, increasingly painful or draining insertion site — seek urgent medical care now
You want the pellet physically removed, your implant record is missing, your estradiol dose was high or unknown, or you are having a serious reaction — start with in-person care

Switching From Hormone Pellets to Patches: The Bottom Line

Your question	The verified answer
Can I switch?	Yes, with a prescriber and a written transition plan.
Do I need to wait until the pellet is gone?	No universal waiting period exists. The start date must be set for your case; do not create your own overlap.
What patch equals my pellet?	None. There is no validated conversion. Group-average blood levels can be compared, but they cannot select your patch.
How long can a pellet keep releasing?	In older studies summarized in a 2026 review, 25 mg estradiol pellets produced a months-long curve; higher-dose studies sometimes showed longer persistence. Your reinsertion date is not a clearance date.
Will I crash?	No one can promise that. Pellet levels generally decline rather than switch off, but symptoms can return before, during, or after the handoff.
Can the pellet be removed?	There is no routine, reliable at-home reversal. Removal requires in-person assessment and may not be feasible.
What if testosterone was included?	An estradiol patch replaces only the estrogen decision. Testosterone is separate, prescription-only, and federally Schedule III.
Do I still need progesterone?	If you have a uterus and use systemic estrogen, you need a clinician-specified endometrial protection plan, usually an adequate progestogen.
What do I do first?	Get the insertion date and the milligrams of every implanted hormone. Do that before paying for a patch program.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Jump to the blood-level comparison — and why it is not a conversion →

Before You Go Further: Get These Three Facts

You cannot build a clean handoff without them.

1. The date of your last insertion.
2. The dose of every hormone, in milligrams. Not “three pellets.” Not “my usual.” Milligrams.
3. Whether testosterone was included — and, if it was, the milligram amount.

“I'm on BioTE” is a brand answer, not a dose answer. A pellet count does not tell a new prescriber what was implanted unless the record also identifies the strength of each pellet.

When the clinic is a HIPAA-covered provider, federal access rules generally give you the right to see and receive a copy of the medical information in your designated record set. That includes medical records, billing records, prescriptions, laboratory reports, and other records used to make decisions about you, subject to limited exceptions. A covered entity generally has 30 calendar days to act on an access request.

We put a copy-and-paste request near the bottom of this page. Send it today. It is the single highest-value thing you can do before the consult.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

Get your personalized action plan → Find My HRT Path

Record-access source: U.S. Department of Health and Human Services, HIPAA right of access.

How Does Switching From Hormone Pellets to Patches Work?

Switching is a prescriber-led handoff, not a milligram-for-milligram swap. The clinician reviews what was implanted and what may still be releasing, decides whether systemic estrogen remains appropriate, sets a patch product and start date, and separately resolves testosterone and uterine-protection questions. The written plan matters more than any internet “equivalent dose.”

Here is the part that should lower the temperature: you are not trapped in another insertion just because no conversion table exists. The lack of a formula does not block the switch. It changes what a competent switch looks like.

Switching is really three decisions, not one

1. The estrogen decision. Is systemic estrogen still appropriate, which FDA-approved product and delivery rate will be used, and when will it start?
2. The testosterone decision. Only if testosterone was implanted. An estradiol patch does not cover it.
3. The uterus decision. If you have a uterus and use systemic estrogen, what exactly is the progestogen plan?

Most pellet programs bundle those questions into one procedure. The cleanest exit is to unbundle them.

“I'm due for my next pellet” is not a pharmacokinetic result

A reinsertion date is the clinic's treatment schedule. It is not proof that the prior pellet has stopped releasing hormone, and it is not automatically the right day to apply a patch.

That difference is why two women with the same nominal pellet dose may leave on different timelines. Insertion date, exact hormone amounts, symptoms, adverse effects, uterus status, current progestogen, medical history, and the reason for switching all matter.

The FDA label contains a gap — and that gap is the answer

The FDA-approved Vivelle-Dot prescribing information gives instructions for women switching from oral estrogen or another estradiol patch. It does not give an instruction for a woman leaving an estradiol pellet.

There is no FDA-approved estradiol pellet in the United States, so an approved patch label has never had to publish a pellet-to-patch schedule. We also found no major menopause guideline that supplies a universal wait, overlap, or conversion rule.

That means a responsible plan is written from your records and clinical response. It is not copied from a package insert, guessed from the next-insertion date, or reverse-engineered from a serum number.

Get these seven items in writing

Before the visit ends, you should know:

1. The exact patch name or generic description
2. The delivery rate and wear schedule
3. The start date — not “around when the pellet fades”
4. The progestogen plan, if you have a uterus
5. What happens to any testosterone decision
6. What to do if the pharmacy cannot fill the exact product
7. When you will be reassessed and how to reach the prescriber before then

Primary source: Vivelle-Dot FDA-approved prescribing information.

How Long Does an Estradiol Pellet Take to Wear Off?

There is no personal countdown clock. Older pharmacokinetic studies summarized in a 2026 peer-reviewed review found that 25 mg estradiol pellets could maintain group-average serum levels for several months and remain above baseline for up to roughly six months; higher-dose studies sometimes showed longer persistence. Individual levels varied substantially.

This is where “three to six months” becomes dangerous shorthand. It can make six months sound like an expiration date. It is not.

A 2026 narrative review assembled older estradiol-pellet studies with different products, doses, study designs, and populations. The most useful published patterns were:

Study pattern summarized in the review	Reported group-level finding	What it can tell you	What it cannot tell you
25 mg estradiol pellet	Mean serum estradiol around 50–70 pg/mL for about three months, followed by decline that remained above baseline for up to about six months	A 25 mg implant can have a long tail	Your exact level, symptom threshold, or safe patch start date
European 25 mg implant	Peak around 68 pg/mL, then roughly 40–60 pg/mL across weeks 2–24	Some commercial implants produced months of exposure	That a U.S. compounded pellet behaves identically
Two 25 mg pellets	Mean around 113 pg/mL in the first week and reported as stable across 24 weeks in one study	More implanted estradiol can produce higher and prolonged exposure	That 50 mg always produces 113 pg/mL or clears at 24 weeks
Higher-dose observational data	Some women remained above baseline beyond six months	“Six months” is not a hard ceiling	An individual removal or transition schedule

The review itself stresses substantial person-to-person variability and the lack of modern direct comparative trials. That matters more than the tidy averages.

Detectable is not the same as effective

A pellet can still be releasing estradiol after your symptoms have returned. Your symptom threshold is not the same as a laboratory's lower limit of detection.

That explains the otherwise confusing experience of feeling “due” while hormone may still be present. It also explains why starting a patch purely by calendar can create too much exposure for one woman and an avoidable symptom gap for another.

The finding to carry into the consult

Your reinsertion date is not the day your pellet reaches zero. That is the fact to carry into the consult.

Source: Jacobsen L, et al. “Subcutaneous Estradiol Pellets as Hormone Therapy in Menopause: Clinical Pharmacology, Patient Selection and Safety Considerations”, Journal of Clinical Medicine 2026;15:48. This is a narrative review of heterogeneous, mostly older studies—not a pellet-to-patch trial.

What Patch Dose Equals a Hormone Pellet?

No patch dose equals a hormone pellet. There is no validated one-to-one conversion, and FDA labeling warns that serum estrogen concentration does not predict an individual woman's response or adverse-outcome risk. Published patch and pellet blood levels can be placed side by side, but the overlap is context for a prescriber—not a dosing instruction.

This is the question you came for, so here is the honest version with the numbers left intact.

What follows is: an original cross-source comparison of reported group-average estradiol exposure.

What follows is not: a conversion table, a starting-dose calculator, proof of equal symptom control, or permission to layer a patch over an active pellet.

What one FDA-approved twice-weekly patch produced in its studies

The Vivelle-Dot label reports steady-state pharmacokinetic values in postmenopausal women. In those studies, the average baseline estradiol concentration was 11.7 pg/mL.

Patch delivery rate	Application site	Peak concentration (Cmax)	Average concentration (Cavg)	Trough concentration (Cmin)
0.0375 mg/day	Abdomen	46 pg/mL	34 pg/mL	30 pg/mL
0.05 mg/day	Abdomen	83 pg/mL	57 pg/mL	41 pg/mL
0.075 mg/day	Abdomen	99 pg/mL	72 pg/mL	60 pg/mL
0.1 mg/day	Abdomen	133 pg/mL	89 pg/mL	90 pg/mL
0.1 mg/day	Buttock	145 pg/mL	104 pg/mL	85 pg/mL

The application site changed exposure in the label study. Transdermal delivery also showed substantial between-person variability. Those two facts alone should kill the fantasy of an exact internet conversion.

What selected pellet studies reported

Implanted estradiol in the reviewed study	Reported group-average pattern	Superficial overlap with the patch table	The limit that matters
25 mg	Roughly 50–70 pg/mL for about three months, then a gradual decline	Numerically overlaps average exposure reported for 0.05 and 0.075 mg/day patches	Different studies, products, methods, timing, and people; not interchangeable doses
25 mg European implant	Peak around 68 pg/mL, then roughly 40–60 pg/mL through 24 weeks	Numerically crosses several patch values	Does not establish the right U.S. product, strength, or start date
50 mg total	Around 113 pg/mL in one study	Above the abdominal Cavg reported for the 0.1 mg/day patch and near the buttock Cavg	Does not prove a “ceiling,” equivalent effect, or need for multiple patches

What the overlap can tell you

A pellet's milligram number and a patch's mg/day number are different measurements and cannot be compared directly
Some published group-average serum ranges overlap
A woman leaving a higher or unknown pellet dose deserves more careful transition planning, not more aggressive internet arithmetic
The highest delivery rate in this label's table is not a license to recreate a prior pellet blood level

What the overlap cannot tell you

Which patch strength you should receive
Whether hormone is still releasing from your pellet today
Whether an overlap is appropriate
Whether a matching serum number would produce matching symptom relief
Whether a matching serum number would carry matching risk
Whether you should add, cut, stack, or change patches

The current estradiol transdermal label says the quiet part directly: serum estrogen concentration generally does not predict an individual woman's therapeutic response or adverse-outcome risk, and exposure comparisons across estrogen products may not be valid for inferring individual efficacy or safety.

If your record shows 50 mg or more — or no one can tell you the dose

This is not where you “round up” to the highest patch rate.

It is where you choose a clinician who is comfortable with complex menopause care, can review the implant record and current symptoms, and can monitor a transition that may not fit a standard telehealth pathway. If the online intake cannot accept your record or explain the plan, use an in-person menopause clinician. The Menopause Society practitioner directory is a non-affiliate place to start.

Sources: Vivelle-Dot prescribing information; current estradiol transdermal system labeling; Jacobsen et al. 2026.

Will You Crash When You Switch From Pellets to a Patch?

A crash is possible, but it is not inevitable and it cannot be predicted from a chart. Pellet exposure generally declines over time instead of stopping on one fixed day; the patch begins delivering estradiol after application, but symptom control is assessed over days and weeks—not by the first detectable rise in a blood level. The start date is the handoff.

This is fear number one. A clean answer matters because a slow decline is not the same as a guaranteed smooth handoff.

A slow pellet decline does not guarantee a smooth experience. Symptoms can return while the pellet is still detectable. They can also change after a new route starts. That does not mean the switch failed. It means blood concentration, tissue response, symptom response, and timing are related without being interchangeable.

The patch is fast in one narrow sense

In the Vivelle-Dot pharmacokinetic study, serum estradiol rose above baseline within hours of application. That tells us the patch begins delivering drug promptly.

It does not mean hot flashes, sleep, mood, or cognition must improve within hours. Clinical symptom trials measure response over longer intervals, and individual response varies.

The real reason a patch is easier to manage

After a Vivelle-Dot patch was removed, serum estradiol and estrone returned to baseline within about 24 hours in the label study. A pellet cannot be peeled off at home, and its release may continue for months.

That is the clean contrast: a patch gives the prescriber an off switch. A pellet does not.

Do not turn “24 hours” into a promise that every symptom or side effect disappears in one day. It is a pharmacokinetic statement about average serum levels after patch removal.

The handoff shape you want

Not this:

pellet → guessed gap → panic → self-added patch

This:

records → clinician-set start date → exact product → backup fill plan → scheduled reassessment

That sequence is less dramatic because it removes the moment where you are improvising while symptoms are loud.

Ready to line up the estrogen decision before the next insertion date?

For a documented, straightforward estrogen route change, Midi Health is the strongest online starting fit we verified for women using commercial PPO insurance. Midi is available in all 50 states, is in-network with most major PPO plans, and offers FDA-approved estradiol patches. Its separate testosterone program says it does not prescribe testosterone pellets. Your plan, deductible, copay, clinical eligibility, medication cost, and transfer acceptance still have to be confirmed.

Check Midi coverage for your plan and state → A visit is an evaluation, not a guaranteed prescription. The clinician decides what is appropriate.

Can a Hormone Pellet Be Removed Early?

There is no routine removal process comparable to taking out a contraceptive implant. Menopausal estradiol pellets are compounded and designed to release over time; locating or removing remaining material may be difficult or inappropriate. A severe reaction, infection, extrusion, or request for removal belongs with an in-person clinician or surgeon—not a telehealth switch plan.

The practical answer is: do not build your transition around successful removal.

By the time removal is considered, a pellet may be difficult to locate or remove. A current insurer medical policy—one payer's policy, not a national rule—lists difficulty reversing the drug, problems removing pellets if therapy must stop, infection, extrusion, discomfort, fluctuating levels, and inflexible dosing among the route's concerns. FDA-approved Testopel labeling for male hypogonadism also acknowledges that adverse effects may require pellet removal.

Neither source creates a standard removal protocol for compounded menopausal estradiol pellets.

Call today instead of continuing to research if:

The insertion site is increasingly red, hot, swollen, draining, or severely painful
You have fever or feel acutely unwell after an insertion
You have severe or frightening new symptoms
A clinician has told you the pellet may need to be located or removed

This section has no product recommendation on purpose. A website cannot examine an insertion site or remove an implant.

Sources: current payer policy on implantable hormone pellets for females; Testopel FDA labeling.

What if Your Pellet Contained Testosterone Too?

An estradiol patch replaces only the estrogen route. Testosterone is a separate prescription decision, is federally Schedule III, and has no FDA-approved product specifically indicated for women in the United States. Continuing it may require a different clinician, laboratory work, a separate visit, and a non-pellet route; a patch-only service cannot promise continuity.

Here is the limitation that can change your destination.

If your implant contained estradiol and testosterone, you are not replacing one product with one product. You are breaking one irreversible bundle into two adjustable decisions.

That can feel like bad news because the pellet program made both hormones look like one treatment. It is also the advantage of leaving: each hormone can now earn its place separately.

The estrogen and testosterone questions are not the same

Estradiol decision	Testosterone decision
Is systemic estrogen still appropriate?	What symptom is testosterone meant to treat?
Which FDA-approved product and delivery rate?	Does that symptom fit the evidence-based indication?
When does the patch start?	Is testosterone still releasing from the pellet?
What is the uterine-protection plan?	Which licensed prescriber can evaluate, prescribe, and monitor a Schedule III drug in your state?
What is the shortage backup?	Which non-pellet formulation is being proposed, and is it FDA-approved or compounded?

What the evidence actually supports

The 2019 Global Consensus Position Statement on testosterone therapy for women is much narrower than pellet marketing.

Its only evidence-based indication is hypoactive sexual desire disorder in postmenopausal women after a formal biopsychosocial assessment. Across trials, the average benefit was modest—about one additional satisfying sexual event per month above placebo. The statement found insufficient evidence or no demonstrated benefit for general wellbeing, depressed mood, cognition, and several other broad claims.

It also says its recommendations do not apply to pellets, injectables, compounded preparations, or any formulation that produces supraphysiologic blood concentrations.

That is worth sitting with. If you were given testosterone for “energy,” “brain fog,” or a generic optimization target, the switch is the moment to ask what problem it is solving and whether another cause has been checked.

Testosterone is not a casual add-on

Federal regulations list testosterone as a Schedule III controlled substance. It requires a prescription, and access depends on federal rules, state law, clinician licensing and registration, platform policy, laboratory requirements, and clinical judgment.

There is no FDA-approved testosterone product specifically indicated for women in the United States. Testopel is an FDA-approved testosterone pellet for certain forms of male hypogonadism; that does not make testosterone pellets approved for menopausal women.

What the three online services we checked publish

Midi Health: offers a compounded testosterone program in 25 states. Its published process requires an initial menopause evaluation, laboratory testing and review, and usually a second visit before a treatment decision. Midi explicitly discloses that the compounded testosterone is not FDA-approved and says it does not prescribe testosterone pellets.
Winona: says it does not prescribe testosterone.
Sesame: says providers on its platform cannot prescribe controlled substances online.

That is the damaging admission: two of the three services compared below cannot continue testosterone, and the third does not promise it. Finding that out here is better than finding it out after an intake form and a credit-card charge.

If continuing testosterone is non-negotiable

A patch-only subscription is the wrong destination. Start with a clinician experienced in female sexual medicine or complex menopause care and ask for a separate testosterone assessment. Do not assume that DHEA is an interchangeable substitute; it is a different product and decision.

If you need one service to evaluate both decisions

Among these three online services, Midi is the only one that publicly offers both FDA-approved estradiol routes and a separate compounded-testosterone pathway in eligible states. The estradiol patch is FDA-approved; the compounded testosterone is not. The testosterone pathway involves its own assessment, labs, state availability, and prescribing decision.

See Midi's current testosterone process and state availability → Sources: Global Consensus Position Statement on Testosterone Therapy for Women; 21 CFR §1308.13 Schedule III; Testopel labeling; Midi testosterone program; Winona FAQ; Sesame menopause program.

Do You Still Need Progesterone When You Switch to a Patch?

If you have a uterus and use systemic estrogen, you need a clinician-specified plan to protect the endometrium, usually with an adequate progestogen. Changing from a pellet to a patch does not erase that requirement. Your prior progesterone product, dose, route, and schedule must be reviewed rather than silently carried forward.

Read this section twice if you still have a uterus.

Systemic estrogen stimulates the uterine lining. Adequate progestogen reduces the risk of endometrial hyperplasia and endometrial cancer in women with a uterus who use systemic estrogen.

The FDA warning that stayed

In November 2025, FDA initiated labeling changes for menopausal hormone therapy. In February 2026, FDA approved the first six updated product labels.

The boxed warning about endometrial cancer with systemic estrogen-alone treatment stayed.

That does not mean every woman uses the same progesterone product or schedule. It means “I was taking something before” is not a complete protection plan.

Bring these questions:

Do I have a uterus, and do my surgical records clearly confirm what was removed?
Which progestogen will I use with this systemic patch?
What dose, route, and schedule?
What bleeding should trigger a call or evaluation?
If I use a levonorgestrel IUD, does the clinician consider it adequate for this plan and duration?

If you had a hysterectomy, progestogen may not be needed for endometrial protection—but do not reconstruct your surgical history from memory if you are unsure what was removed.

Any unexplained vaginal bleeding is evaluated before the hormone change. Not after the first refill. Before.

Sources: FDA November 2025 announcement; FDA approval of updated labels, February 2026; estradiol transdermal system labeling.

What Does Switching From Pellets to a Patch Actually Cost?

There is no honest national pellet price or universal patch price. Three clinics publishing current female-pellet fees list $425 to $700 for an insertion, with different consult, laboratory, and follow-up charges. One current cash-pharmacy example lists eight 0.1 mg twice-weekly patches at $39.18. Compare the whole care model—not one headline number.

National-looking price ranges are not reproducible enough for a buying decision. Here is the tighter version: named prices, named inclusions, one date.

Three published pellet-program examples checked August 31, 2026

Clinic-published female pellet price	Published interval	Other published charges	What the number does not prove
Contemporary Health Center: $425 per insertion	Typically 3–5 months	Laboratory work and additional medical visits are excluded	A national average, your dose, or your total first-year cost
Xena Health: $450 per insertion	3–4 months	Initial consultation $250; follow-up appointment $150	That every patient pays only the insertion fee
Alchemy Clinic: $700 initial insertion; $600 subsequent insertions	Subsequent insertions every 3–4 months based on symptoms	Consultation $250; initial labs $250	That this higher-cost program represents the market

These are examples from three clinic pages, not a survey of every pellet practice. They show why a single “pellet price” hides the part that lands on your card: consultation, labs, insertion, supplements, follow-up, and reinsertion cadence.

One exact cash-patch example

Mark Cuban Cost Plus Drug Company listed one box of eight Dotti 0.1 mg/24-hour twice-weekly patches at $39.18 when checked August 31, 2026. That is one manufacturer, one strength, one quantity, and one pharmacy—not a promise about your prescription or final checkout.

Your actual medication cost can change with:

The prescribed strength and once-weekly versus twice-weekly product
Brand versus generic dispensing
Pharmacy inventory
Insurance formulary, deductible, and copay
Coupon or cash-price terms
Shipping and taxes, where applicable

What online care adds to the medication price

Care route	Published care price checked August 31, 2026	Medication and laboratory handling	The cost question to ask before paying
Midi Health with commercial insurance	Standard plan cost-sharing; Midi says it is in-network with most major PPO plans	Medication goes through the pharmacy benefit; testing depends on the clinical plan and coverage	“Is Midi in-network for my exact plan, and what will the first and follow-up visits cost?”
Midi Health self-pay	$250 initial visit; $150 continued-care visit	Medication and outside services are separate	“How many visits does this transfer usually require, and what is not included?”
Winona estrogen patch	From $149 per month	Provider-stated price includes the prescription program, physician messaging, and standard shipping	“Is $149 the price for my prescribed patch and supply schedule, and when will the first refill process?”
Sesame menopause subscription	$59 per month	Medication costs are separate; the program says basic labs are included when clinically necessary	“What is my provider's exact monthly price, and which medication and lab charges remain separate?”
Local clinician + pharmacy	Varies by clinician and plan	Patch filled locally under insurance, coupon, or cash terms	“What is the visit price, and what does my pharmacy charge for the exact product and quantity?”

The cheapest route may earn us nothing

If you already have a clinician who can review the pellet record, write an FDA-approved estradiol prescription, and follow the transition, a local visit plus a generic pharmacy fill may be the lowest-cost route.

We make nothing from that answer. It is still the first route to price.

Telehealth earns its place when the local route is unavailable, dismissive, booked for months, outside your plan, or unable to manage the transfer you need. Do not pay a subscription merely to obtain a prescription you can already get safely and affordably.

Does insurance cover pellets?

Do not turn one payer policy into a national rule. Check your plan.

Pellet insertion is commonly billed with CPT 11980. One current BlueCross BlueShield medical policy classifies implantable hormone pellets for women as investigational and not covered under that policy. Your employer plan, insurer, diagnosis, claim, and benefit language can differ.

Look at an old Explanation of Benefits, search for 11980, and ask the plan:

1. Was the insertion denied, excluded, or applied to a non-covered service?
2. Were the consultation and laboratory claims handled separately?
3. Is an FDA-approved estradiol patch on the formulary?
4. Is prior authorization required for the exact product?
5. Which pharmacies can fill it at the lowest plan price?

That five-minute call is worth more than another generic cost article.

Commercial PPO plan? Check Midi's current coverage before booking → Sources checked August 31, 2026: Contemporary Health Center pricing; Xena Health pricing; Alchemy Clinic pricing; Cost Plus Drugs Dotti 0.1 mg; Midi HRT pricing; Winona estrogen patch; Sesame menopause treatment; current payer policy.

Is There an Estradiol Patch Shortage Right Now?

Yes—but it is product-specific, not a statement that every estradiol patch is unavailable. ASHP's bulletin, updated August 12, 2026, lists affected manufacturers, strengths, and package sizes while also listing available products. Build a backup fill plan before the start date, and never cut, stack, or substitute patches on your own.

This is the current fact that can derail an otherwise good handoff at the pharmacy counter.

ASHP's active shortage bulletin names affected Sandoz, Amneal Dotti, Viatris, Noven, and Zydus products. The same bulletin says Lyllana is currently available, lists Climara once-weekly patches as available, and lists multiple Mylan/Viatris products as available.

So the useful sentence is not “patches are impossible to find.” It is this:

Your exact manufacturer, strength, package, and wear schedule may be unavailable even while another FDA-approved estradiol patch is on the shelf.

Build this backup ladder with the prescriber

Ask in this order:

1. Can another pharmacy fill the exact prescription? Start with the same product, strength, and schedule.
2. Is another FDA-approved patch product or wear schedule clinically appropriate? A pharmacist or prescriber must resolve the substitution; you do not.
3. Would another FDA-approved transdermal route fit? Estradiol gels and sprays preserve the through-the-skin route but have their own dosing and application instructions.
4. Would another FDA-approved systemic route fit? Femring or oral estradiol may be options for some women, with different tradeoffs and contraindications.
5. Only then discuss compounded therapy. Ask why an FDA-approved option is unsuitable or unavailable, which pharmacy will compound it, and how its non-FDA-approved status changes the decision.

FDA-approved and compounded products are not interchangeable categories. Compounded drugs are not FDA-approved, and FDA does not review the finished product for safety, effectiveness, or quality before marketing.

Do not manufacture your own strength

Do not:

Cut a patch unless the exact product information and your pharmacist or prescriber explicitly support it
Apply two patches to recreate a higher delivery rate
Change once-weekly to twice-weekly use—or the reverse—without a new instruction
Substitute a different brand, strength, or route because the numbers look close
Wait until you are out before telling the prescriber the pharmacy cannot fill it

ASHP explains why: reservoir patches should never be cut, and cutting a matrix patch can produce uneven release and variable therapy. That is a pharmacy problem, not a kitchen-scissors solution.

The shipped option—and its limit

Winona states that its estradiol patch is FDA-approved and publishes a patch program from $149 per month, with free shipping. Its patch page lists five strengths, and the service says it treats women ages 35–59 across its published state roster, currently 37 states plus Puerto Rico.

That can bypass your local pharmacy workflow. It does not guarantee that Winona will accept an active-pellet transfer, approve a prescription, stock every strength on the day you order, or deliver before the clinician-set start date. Confirm all four before relying on it as the handoff.

Winona is an automatically refilling subscription. Its cancellation policy gives a 24-hour window after an order processes and before pharmacy fulfillment begins. After that window, an order cannot be canceled, refunded, or returned.

Check Winona's current price, age gate, and state availability → Sources checked August 31, 2026: ASHP Estradiol Transdermal System shortage bulletin; FDA on compounded drugs; Winona patch page; Winona state and age page; Winona cancellation policy.

Who Can Prescribe the Patch—and Which Care Model Fits This Switch?

A clinician with prescribing authority in your state can prescribe an FDA-approved estradiol patch when clinically appropriate. The harder question is who will accept a recent pellet patient, review the implant record, address testosterone and uterine protection, and remain reachable during the handoff. For most commercially insured women, Midi is the strongest online starting fit; other situations route elsewhere.

This is an editorial fit decision based on the published facts below. It is not a guarantee of treatment, prescription, insurance payment, inventory, or transfer acceptance.

Provider-stated versus directly checked: August 31, 2026

Decision fact	Midi Health	Winona	Sesame	What still must be confirmed
Care format	Scheduled virtual clinician visits	Online intake and secure messaging; no required phone or video visit with the physician	Video visits plus provider messaging	Whether the format can safely handle your active pellet and records
FDA-approved estradiol patch	Offers FDA-approved estradiol forms including patches	Provider states its estrogen patch is FDA-approved	Lists menopause prescriptions sent to a local pharmacy when clinically appropriate	Exact product, manufacturer, strength, and pharmacy stock
Published care price	Insurance cost-sharing or $250 initial / $150 follow-up self-pay	Patch from $149/month, shipping included	$59/month; medication separate	Your checkout price and every excluded cost
Insurance	In-network with most major PPO plans; coverage varies	Does not bill insurance; accepts HSA/FSA	Cash-pay care; medication may be processed separately at the pharmacy	Exact plan treatment of visits, medication, and labs
Medicare	Not covered; Medicare beneficiaries may self-pay but cannot submit Midi-related claims	No insurance billing	No insurance billing	Whether local Medicare-covered care is cheaper and more appropriate
Medicaid / Medi-Cal	Cannot treat these patients, even self-pay	No insurance billing; confirm eligibility directly	Cash-pay; confirm program eligibility	A local or plan-directed route
Geography	All 50 states	Published roster of 37 states plus Puerto Rico	Provider availability varies by state	Your current state at intake and follow-up
Age gate	No blanket age cutoff published on the HRT page	HRT plans limited to ages 35–59	No blanket age cutoff published on the menopause page	Individual clinical eligibility
Testosterone	Separate compounded, non-FDA-approved pathway in 25 states; labs and usually two visits before a decision	Does not prescribe testosterone	Online providers cannot prescribe controlled substances	Whether testosterone continuity is a priority and who will manage it
Pellet position	Testosterone program says it does not prescribe testosterone pellets	Says it does not prescribe pellet therapy	No pellet-transfer policy located on the program page	Whether the service will accept your exact transfer
Laboratories	Ordered when clinically indicated; testosterone pathway publishes baseline and follow-up testing	Says routine hormone testing is generally not required for its model	Program says basic labs are included when clinically necessary; confirm any state-specific limitation at checkout	Which tests are required, where they are drawn, and who pays
Cancellation / refill	Visit-based pricing; booking and care terms depend on coverage	Auto-refill subscription; 24-hour cancellation window after an order processes	Self-cancel before the next billing cycle; no refund after the initial visit or for prior months	The deadline before the next charge or pharmacy fulfillment

Pick the route that fits the fact pattern

You have commercial PPO insurance, a documented estradiol dose, and a straightforward route-change request → start with Midi. The visit can run through insurance, the patch can run through the pharmacy benefit, and the video format gives you a place to show records and ask for a written handoff.

Check whether Midi is in-network for your exact plan → You are paying cash, you are 35–59, you live in a served state, you prefer asynchronous care, and you want medication shipped → compare Winona. The published $149 starting price is easy to understand, but the age gate, state list, automatic refills, and active-pellet transfer all need confirmation.

See Winona's current patch price and eligibility → You want a cash-pay video visit and a prescription sent to your own pharmacy → compare Sesame. Its menopause program is $59 per month, but medication is separate and its providers cannot prescribe controlled substances online. That makes it an estrogen-only route for this comparison—not a testosterone-continuity solution.

See Sesame's current menopause program terms → You have Medicare → price local care first. Midi permits Medicare beneficiaries to self-pay but does not bill Medicare and says those patients cannot submit claims related to Midi care. Winona and Sesame do not bill insurance for these programs. A local clinician using your Medicare benefits may be the better starting point.

You have Medicaid or Medi-Cal → do not start with Midi. Midi explicitly says it cannot treat those patients even as self-pay. Use your plan directory, primary-care office, gynecology clinic, or a local menopause service.

You are 60 or older → Winona is not available for a new HRT plan. Compare Midi, a local clinician, or an in-person menopause specialist.

Your pellet dose is high, unknown, or contradictory; testosterone continuity is the priority; you want removal; you have unexplained bleeding; or your history is complex → start in person. This is not the moment to squeeze yourself through a standard online funnel.

Your main problem is vaginal dryness, painful sex, or urinary symptoms—not hot flashes or night sweats → ask whether local vaginal estrogen is the primary tool. A systemic patch and local vaginal treatment solve different problems, and some women use both. Read our vaginal estrogen guide before paying for a systemic-only plan.

The transfer question none of the provider pages answers

We found published information on price, geography, insurance, routes, age limits, labs, testosterone, and cancellation. We did not find a provider page that promises it will take over every woman with a currently releasing pellet.

Ask this before checkout:

“I currently have an implanted hormone pellet. My last insertion was [date] and the record shows [hormone and milligrams]. Will your clinician review the implant record and create a written pellet-to-patch start plan, including progesterone and testosterone if relevant, before medication is dispensed?”

A clear yes, no, or “the clinician must evaluate that first” is useful. A sales answer that never addresses the active implant is not.

Provider facts checked on the providers' own pages August 31, 2026. Prices, state coverage, insurance participation, formularies, inventory, and policies can change. Confirm during intake and at checkout.

Do You Need Blood Work Before Switching?

Not automatically for hot flashes and night sweats. FDA-approved estradiol patch labeling states that serum FSH and estradiol levels have not been shown useful for managing moderate-to-severe vasomotor symptoms. Targeted testing can still matter when the pellet record is missing, testosterone was implanted, adverse effects are present, or another condition may explain the symptoms.

If you came from a pellet clinic where each cycle revolved around a hormone panel, this may feel wrong. It is not a rejection of laboratory medicine. It is a distinction between two questions.

Question one: “Do I need a blood estradiol number to prove my hot flashes deserve treatment?” Usually no.

Question two: “Does this unusual transition create a reason to test something specific?” Sometimes yes.

A clinician may reasonably order targeted testing when:

The implant record is missing, incomplete, or inconsistent
Testosterone was implanted and androgen effects or continued treatment are being assessed
You have new hair growth, acne, scalp hair loss, voice change, or other possible androgen effects
Symptoms could reflect thyroid disease, anemia, diabetes, medication effects, or another diagnosis
The history creates a separate monitoring need
The clinician is considering a testosterone prescription, which involves a different evidence and monitoring pathway

What no lab can tell you

A single blood draw cannot tell you:

The exact day the pellet will stop releasing
Which patch strength will feel best
Whether your symptoms are entirely hormonal
Whether an overlap is safe for you
Whether a compounded pellet behaved like a published study product
Whether a telehealth service will accept the transfer

Use a lab to answer a defined clinical question. Do not use one as a substitute for the implant record and a written plan.

Source: current estradiol transdermal system labeling, Laboratory Tests.

What Records Should You Request From the Pellet Clinic?

Ask for the actual record, not a verbal summary. The handoff is strongest when the new clinician can see the insertion date, every hormone and milligram amount, product or pharmacy information, procedure note, laboratory results, current prescriptions, and adverse-event notes. HIPAA gives you access to existing records; it does not force a clinic to recreate information it never documented.

Copy and paste this:

Subject: Request for complete hormone-pellet treatment records
Please send me an electronic copy of the records from my hormone-pellet treatment, including:
- The date of each insertion - The name of every hormone implanted - The milligram strength and number of each pellet - The total milligrams implanted for each hormone - The compounding pharmacy or manufacturer, product name, lot number, and beyond-use or expiration date, if documented - The procedure note and insertion site - All laboratory results used before or after insertion - My current and prior progesterone or progestogen prescriptions - Any documented adverse effects, calls, messages, or treatment changes - Billing codes and itemized charges related to the insertion
Please provide the records in electronic form. I am requesting access under the HIPAA right of access, to the extent the requested information is maintained in my designated record set.

Do not ask the receptionist to translate “four pellets” into a dose from memory. Ask for the document.

What if the record is incomplete?

Send the new clinician what you have and label every gap plainly:

Fact	Known	Missing
Last insertion date
Estradiol milligrams
Testosterone milligrams
Other implanted hormones
Uterus status
Current progestogen
Compounding pharmacy or product
Last relevant labs
Current symptoms or adverse effects

A blank is safer than a guessed number. “Unknown” is clinical information.

Source: HHS HIPAA access guidance.

Build Your Pellet-to-Patch Transition Handoff

This worksheet does not calculate a dose or start date. It turns the facts scattered across your records, memory, pharmacy, insurance, and symptoms into one page a clinician can use. Complete it before the visit, attach the implant record, and leave blanks where the answer is genuinely unknown.

Your implant record

Field	Your answer
Last insertion date
Estradiol total dose in mg
Testosterone total dose in mg
Other hormones in the pellet
Clinic and clinician
Compounding pharmacy or manufacturer
Product or lot information
Insertion site
Planned reinsertion date

The three-decision handoff

Decision	What the new clinician needs to know
Estrogen	Symptoms you want treated; why you are leaving pellets; preferred route; prior reactions; exact patch/product questions
Testosterone	Whether it was implanted; why it was prescribed; whether you want it reassessed; possible androgen effects
Uterus / progestogen	Whether you have a uterus; surgical history; current progestogen product, dose, route, and schedule; bleeding history

Current symptoms

Rate only what is useful for the consult. This is not a diagnostic score.

Symptom	None	Mild	Moderate	Severe	What changed, and when?
Hot flashes
Night sweats
Sleep disruption
Mood or irritability
Vaginal or urinary symptoms
Low sexual desire causing distress
Acne, hair growth, scalp hair loss, or voice change
Bleeding
Insertion-site problem

Your five questions for the new prescriber

1. What exact FDA-approved product and delivery rate are you considering, and why?
2. What date should I start it, and what fact determines that date?
3. What is my endometrial protection plan if I have a uterus?
4. What happens to the testosterone decision?
5. What is the backup plan if my pharmacy cannot fill the prescribed patch?

Bring this page. Do not rely on remembering all five while you are trying to decide whether the clinician understands the problem.

What Are the Seven Steps for Switching From Pellets to a Patch?

The safe sequence is records first, prescription second. Pause the automatic reinsertion, retrieve the implant details, separate estrogen from testosterone and uterine protection, choose the right care setting, get an exact written start plan, secure a shortage backup, and schedule reassessment. Do not self-convert or create your own overlap.

Step 1: Pause the automatic reinsertion

Do not let “your next appointment is due” make the decision for you. You are allowed to stop the cycle long enough to understand the next route.

Pausing a future procedure is not the same as stopping a current prescription. Continue any current medication unless the prescribing clinician tells you otherwise.

Step 2: Get the implant record

You need the date and milligrams before the transition is finalized. Send the records request above.

Step 3: Separate the three decisions

Write estrogen, testosterone, and uterus/progestogen on three lines. Do not let a provider answer only the first one.

Step 4: Name the reason you are switching

Examples:

I want an FDA-approved estrogen product
I want a dose that can be adjusted or stopped
I want to use insurance
I do not want another procedure
I had side effects
I do not know what dose I received
I need a separate testosterone assessment

Your reason changes the right destination.

Step 5: Choose online versus in-person care

A documented, uncomplicated estrogen route change may fit telehealth. High or unknown dose, removal, severe adverse effects, unexplained bleeding, complex history, or testosterone continuity may justify in-person care first.

Step 6: Get the start date, exact product, and backup in writing

“Start when you feel it wearing off” is not a complete plan. Get the date, delivery rate, schedule, progestogen plan, testosterone plan, and shortage fallback.

Step 7: Reassess—do not improvise

Track symptoms and any adverse effects. Use the scheduled follow-up or contact route. Do not cut, stack, add, or stop patches to chase a number or a bad afternoon.

That is the whole transition in one sentence:

Pause the next procedure, get the record, unbundle the hormones, and leave the consult with a written handoff.

What The HRT Index Actually Verified

We checked the label gap, pharmacokinetic tables, pellet literature, testosterone status, endometrial warning, shortage bulletin, record-access rule, payer policy, and every provider or clinic price published on this page. We did not pretend public websites can verify your individual dose, pharmacy stock, exact shipped manufacturer, insurance claim, or acceptance as a transfer patient.

This page follows The HRT Index Verification Standard. We evaluate care using five pillars, in this exact order: clinical legitimacy, care quality, medication fit, price transparency, access.

Verified against primary or first-party sources

FDA-approved estradiol transdermal labeling and pharmacokinetic tables
FDA's 2025–2026 menopausal hormone therapy labeling actions
FDA's current compounding language
The peer-reviewed 2026 estradiol-pellet narrative review
The Global Consensus Position Statement on testosterone therapy for women
The federal Schedule III regulation and Testopel label
ASHP's active estradiol transdermal shortage bulletin
HHS HIPAA access guidance
A current payer policy on female hormone pellets
Each provider's own pricing, insurance, state, age, laboratory, testosterone, shipping, and cancellation pages
Each pellet clinic's own published price page

Provider-stated, not independently inspectable before dispensing

The exact manufacturer and NDC Winona will ship
The exact manufacturer a Midi or Sesame patient's pharmacy will dispense
Whether the provider will accept your current pellet transfer
Whether a particular clinician will prescribe the requested route
Whether a specific strength is in stock on the day of prescribing

Those are not small print. They are the questions to carry into intake.

Recheck schedule

Data	Recheck cadence
ASHP patch shortage	Monthly and on publication day
Provider price, states, age gate, insurance, testosterone, cancellation	Monthly
Cash-pharmacy example	Quarterly
Payer policy	Annually and after renewal notices
FDA labeling and regulatory status	On every FDA update
Clinical guidance and peer-reviewed evidence	At least annually and when major guidance changes

Frequently Asked Questions

Can I switch from hormone pellets to an estradiol patch?

Yes. The switch requires a prescriber, the implant record, and a written start plan. There is no validated pellet-to-patch conversion or universal timing rule.

Do I have to wait until the pellet is completely gone?

Not under a universal rule, because no such rule exists. Your prescriber may time the patch before, around, or after symptom return based on the implant record, symptoms, risk history, and clinical judgment. Do not decide the overlap yourself.

How long does a 25 mg estradiol pellet last?

Older studies summarized in a 2026 review found group-average levels around 50–70 pg/mL for roughly three months with a gradual decline that could remain above baseline for about six months. That is a study pattern, not your personal expiration date.

Which patch is closest to a 25 mg pellet?

No patch is a validated equivalent. Some group-average serum values overlap with the 0.05 and 0.075 mg/day values in one patch label, but FDA labeling says cross-product blood-level comparisons cannot establish individual efficacy or safety.

Can I start a 0.05 mg patch because the numbers overlap?

Not from this page. The overlap is not a prescribing instruction. A clinician must choose the product, delivery rate, and start date for your case.

Can the pellet be removed if I feel bad?

Sometimes an in-person clinician may evaluate removal, but there is no routine, reliable removal process for a partly dissolved menopausal pellet. Infection, extrusion, severe pain, or a serious reaction requires prompt in-person assessment.

Are hormone pellets FDA-approved?

Estradiol pellets used for menopause in the United States are compounded and not FDA-approved. Testopel is an FDA-approved testosterone pellet for certain forms of male hypogonadism; it is not approved as menopause treatment for women.

What if my pellet included testosterone?

An estradiol patch does not replace testosterone. Testosterone is Schedule III, and there is no FDA-approved testosterone product specifically indicated for women in the United States. It needs a separate clinical assessment and prescription pathway.

Will I still need progesterone?

If you have a uterus and use systemic estrogen, you need an endometrial protection plan, usually an adequate progestogen. The exact product and schedule are individualized. Unexplained bleeding is evaluated before the switch.

Do I need an estradiol blood test first?

Not automatically for vasomotor symptom management. Patch labeling says serum FSH and estradiol levels have not been shown useful for managing moderate-to-severe hot flashes and night sweats. Targeted testing may still be appropriate for missing records, testosterone, adverse effects, or another suspected condition.

Will switching make me gain weight?

There is no pellet-to-patch trial showing that the route change itself causes a predictable weight change. Weight, fluid retention, appetite, sleep, activity, midlife body-composition changes, and other medical factors can overlap. Bring a clear timeline instead of assuming every change is the patch.

Will insurance cover the patch?

Many plans cover at least some FDA-approved estradiol patches, but the exact product, prior-authorization rule, deductible, copay, and pharmacy network vary. Ask about the exact prescription, not “estradiol patches” as a category.

Will insurance cover pellet removal or the old pellet program?

Coverage varies. One current insurer policy classifies implantable hormone pellets for women as investigational and noncovered. Removal, complications, evaluation, labs, and other services may be handled under different benefits. Ask the plan using the actual claim codes.

Is the patch shortage a reason to stay on pellets?

No. It is a reason to make a backup fill plan. ASHP lists both affected and available products. The shortage does not turn a compounded pellet into an FDA-approved equivalent or justify cutting or stacking patches yourself.

Can an online provider handle the switch?

Sometimes. A documented, uncomplicated estrogen route change may fit online care. High or unknown dose, severe adverse effects, removal, unexplained bleeding, complex risk history, or a non-negotiable testosterone plan may belong in person first.

What if my only symptoms are vaginal dryness, painful sex, or urinary problems?

Ask whether local vaginal estrogen is the primary treatment rather than switching to a systemic patch for that reason alone. Read our vaginal estrogen guide for the local-versus-systemic distinction.

What should I do today?

Request the implant record. Do not book another insertion by reflex, and do not buy a patch program until the provider confirms it will review the active pellet and create a written transition plan.

Sources

Medical and regulatory

Provider, price, and policy pages checked August 31, 2026

Still Not Sure Which Care Path Fits?

You do not need to solve the patch, testosterone, uterus, insurance, state, and safety questions in your head.

Take the free, private 90-second Find My HRT Path quiz. It shows the best-fit online route, two strong backups, and the situations where online care is not the right starting point. No email is required to see your match.

Find My HRT Path →

Educational research only. A licensed clinician makes all diagnosis, prescribing, dosing, timing, and monitoring decisions.

Keep the transition plan specific.

Compare hormone pellets with the patch, review online estradiol patch options, read the vaginal estrogen guide, or use Find My HRT Path before changing a prescribed regimen.

Keep reading: